ACCLAIM

a Phase 3, randomzed, double-blind, placebo-controlled study to investigate the effect of Lepodisiran on the reduction of major adverse cardiovascular events in adults with elevated Lp(a) who have established atherosclerotic cardiovascular disease or are at high risk for first cardiovascular event.